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We have designed and synthesized two radioiodinated analogs of hexadecylphosphocholine in order to 
evaluate their tumor imaging potential. 12-(m [‘251]iodophenyl)dodecyl phosphocholine (NM-324) and 
hexadecyl-2-[N,N-dimethyl-N-(m[‘25I]iodobenzyl)-ammonium] ethyl phosphate (NM-326) demonstrated 
the ability of such compounds to localize in and thereby visualize the Walker 256 tumor in rats. However, 
the tumor avidity of NM-324 was far superior to NM-326. In addition, NM-324 showed excellent tumor 
localization in athymic mice bearing subcutaneous human tumors. 
Introduction 
Various strategies have been employed to achieve 
selective accumulation of a radiopharmaceutical 
within tumor cells. A particular problem associated 
with the currently available agents (e.g. [67Ga]citrate) 
is poor tumor specificity (Merrick, 1984). 
In order to achieve greater tumor specificity, 
numerous laboratories have explored the ability of 
tumor antibodies to serve as carriers for various 
radionuclides (Bejent, 1985; Pietersz et al., 1987; Eger 
et al., 1987; Woo et al., 1988). Studies in our own 
laboratory, on the other hand, have focused on drug 
molecules which have shown an ability to accumulate 
in tumors to serve as carriers of the radiodiagnostic 
probe (Counsel1 et al., 1969; Beierwaltes et al., 1968; 
Huang et al., 1979; Korn et al., 1979). 
Several years ago we became interested in phos- 
pholipid ethers (PLEs) as a result of some pioneering 
studies by Fred Snyder and co-workers (Snyder and 
Wood, 1968, 1969). They found that PLEs, which are 
normally present in low concentration in tissues, 
accumulated in tumor cells as opposed to surround- 
ing normal cells. Moreover, they provided evidence 
that this metabolic difference was at the site involving 
cleavage of the alkyl ether bond and that tumor cells 
as opposed to normal cells had very low concen- 
trations of this alkyl cleavage enzyme. This metabolic 
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E. Counsell, M6322 Medical Science Building I, Depart- 
ment of Pharmacology, University of Michigan Medical 
School, Ann Arbor, MI 48109-0626, U.S.A. 
difference between neoplastic and normal cells 
suggested a means for selectively targeting drug 
molecules to tumors. 
In addition, analogs of the naturally-occurring 
alkyl lysophospholipid are known to exhibit anti- 
tumor and antimetastatic activities. PLE, such as 
rat- 1 -octadecyl-2-methylglycero-3-phosphocholine 
(ET-18-OMe) (Fig. 1), have shown a selective cyto- 
toxicity towards a variety of human and murine 
tumors in both in vivo and in vitro studies (Munder 
et al., 1981; Berdel et al., 1985). Similar antitumor 
activity has been shown for less complex structures 
known as alkylphosphocholines (APC) (Fig. 1) 
(Scherf et al., 1987; Muschiol et al., 1987). APC were 
developed to study the structure-activity relationship 
of alkyl lysophosphocholines as they may represent 
the minimal structural requirement for antitumor 
activity for such PLE-like compounds. In addition, 
hexadecylphosphocholine (He-PC), an APC, has 
been evaluated in a clinical pilot study in breast 
cancer patients with skin involvement. Tumor re- 
gression was seen when He-PC was applied topically 
(Unger et al., 1989). Based on these observations, 
regular phase I trial studies have been started. 
Despite earlier studies by Snyder and Wood (1968, 
1969), the mechanism whereby PLEs accumulate in 
tumor cells is still unknown. 
Based upon what is currently known about the 
accumulation of PLE-like molecules within cancer 
cells, a suitably radioiodinated PLE analog would 
be expected to concentrate within neoplastic cells 
and thereby allow visualization via scintigraphic 
imaging. Accordingly, a radioiodinated analog of 
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Fig. I. rat-I-Octadecyl-2-methylglycero-3-phosphocholine 
(ET-ISOMe) and hexadecylphosphocholine (He-PC). 
the naturally-occurring alkyl lysophosphohpid was 
synthesized for evaluation as a potential tumor- 
localizing imaging agent. rat-1-[12-(m-Iodophenyl)- 
dodecyll-2-methylglycero-3-phosphocholine (NM-294) 
(Fig. 2) (Meyer et al., 1989) was radiolabeled with 
iodine-125 via an isotope exchange procedure. Tissue 
distribution studies with NM-294 in rats bearing the 
Walker 256 carcinosarcoma clearly demonstrated its 
ability to accumulate in the tumor. Although radio- 
activity was also present in non-target tissues at this 
time, clearance of tracer from the tumor was much 
slower and thus provided a suitable tumor to non- 
target tissue ratio at 24 h. As a result of this selective 
accumulation, it was possible to clearly delineate the 
tumor using y-camera scintigraphy. 
In order to assess the structural relationships 













Fig. 2. rac-l-[12-(m-Iodophenyl)dodecyl]-2-methy1g~ycero- 
3-phosphocholine (NM-294), 12-(m-iodophenyl)docecyl 
phosphocholine (NM-324) and hexadecyl-2[N,N-dimethyl- 
N(m-iodobenzyl)ammonium]ethylphosphate (NM-326). 
phosphocholine analogs 12-(m [“‘I] iodophenyl)- 
dodecyl phosphocholine (NM-324) and hexadecyl- 
2-[N,N-dimethyl-N-(m[‘25 I] iodobenzyl) ammonium] 
ethylphosphate (NM-326) were synthesized (Fig. 2). 
This paper describes the synthesis and evaluation of 
these agents as potential tumor-localizing agents. 
Syntheses of m-iodophenyl derivatives of He-PC 
Preparation of I2-(m -iodophenyl)dodecylphospho - 
choline (3). To an ice-cooled solution of 12- 
(m-iodophenyl)dodecanol (1) (Meyer et al., 1989) 
(110 mg, 0.28 mmol) in dry Et,0 (2 mL) containing 
Et,N (0.05 mL, 0.36 mmol) was added dropwise 
2-bromoethyl dichlorophosphate (83 mg, 0.34 mmol) 
in dry Et,0 (1.5 mL). The mixture was stirred at 0°C 
for 10 min and was gently refluxed for 3 h. Additional 
dichlorophosphate (68 mg) and Et,N (0.04 mL) were 
added and the refluxing was continued for an ad- 
ditional 3 h. Water (1 mL) was added and the mixture 
was refluxed for 2 h. After removal of the solvents, 
the residue was dissolved in CHCl,. The CHCl, 
was washed with HzO, 0.1 N HCl and H,O, 
dried and evaporated to dryness. The resulting 
residue was chromatographed on silica gel first with 
CHCI, : MeOH (15 : 1) to remove less polar impurities, 
then with CHCl,: MeOH (8: 1) to elute pure inter- 
mediate 2 (101 mg, 62%) as a glassy solid, which was 
used for the next step without further purification. 
A mixture of 2 (101 mg, 0.18 mmol) and Me,N 
(1.3 mL, 45-50% aqueous soln) in CHCl,: DMF:2- 
PrOH (3: 5: 5) (10 mL) was stirred at 60-C for 6 h. 
After cooling, silver carbonate (63 mg) was added to 
the mixture and the mixture was heated for 2 h. The 
silver salts were removed by filtration with Celite 
and the filtrate was concentrated to dryness. The 
residue was chromatographed on silica gel first with 
CHCl,: MeOH (3 : 1) to remove starting material 
(23 mg), and then with CHCl,: MeOH : H,O 
(65:25:3) to elute pure 3 (59 mg, 61%) as a white 
solid. ‘H-NMR 6: 7.52 (lH, s, Ar-2H). 7.49 (lH, d. 
Ar-4H), 7.12 (lH, d, Ar-6H), 6.99 (lH, t, Ar-SH), 
4.29 (2H, bs, -CC,CH2N), 3.86-3.75 (4H, m, 
-CJ,OPOCH,N), 3.39 (9H, s, N(Me),), 3.26 (bs, 
H,O), 2.52 (2H, t, -CH,P). Anal. calcd for 
C,,H,,INO,P.HzO: C, 48.34; H, 7.58; N, 2.45. 
Found: C, 48.09; H, 7.71; N, 2.45. 
Preparation of hexadecyl 2-[N,N,-dimethyl-N-(m- 
iodobenzyl)ammonium]ethylphosphate (5). To an ice- 
cooled solution of hexadecanol (500 mg, 2.06 mmol) 
in dry Et,0 (15 mL) containing Et,N (0.36 mL, 
2.60 mmol) was added dropwise 2-bromoethyl 
dichlorophosphate (600 mg, 2.48 mmol) in dry Et,0 
(10mL). The mixture was stirred at 0°C for 10min 
and was gently refluxed for 4.5 h. After cooling, water 
(3.5 mL) was added and the mixture was heated at 
60°C for 2 h. The solvents were removed under 
reduced pressure and the resulting residue was dis- 
solved in CHCl,. The CHCl, was washed with H,O, 
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0.1 N HCl and HzO, dried and evaporated to dryness. 
The residue was chromatographed on silica gel 
first with CHCl,: MeOH (15 : 1) and then with 
CHCl,: MeOH (8 : 1) to give pure intermediate 4 
(Hansen et al., 1982) (376 mg, 43%) as a white solid, 
which was used without further purification. A mix- 
ture of 4 (100 mg, 0.23 mmol) and N,N-dimethyl- 
m-iodobenzylamine (304 mg, 1.16 mmol) in EtOH 
(5 mL) was refluxed for 3 days and then for 2 h in the 
presence of Ag,CO, (83 mg). After removal of the 
silver salts by filtration, the filtrate was concentrated 
to dryness under reduced pressure. The resulting 
residue was chromatographed on silica gel with 
CHCl,: MeOH (3: 1) to give pure 5 (41.5 mg, 29%) 
as a white solid. ‘H-NMR 6: 7.91 (lH, s, Ar-2H), 
7.77 (lH, d, Ar-4H), 7.69 (lH, d, Ar-6H), 7.15 
(lH, t, Ar-SH), 4.89 (2H, s, -CC,Ph), 4.40 
(2H, bs, -CC*CH,N), 3.863.80 (4H, m, 
-_CH,OPOCH,CH,N), 3.29 (6H, s, N(Me),) 2.77 
(bs, H,O), 1.55 (2H, m, -CC,OP-), 1.25 (26H, s, 
-(C&,),,), 0.88 (3H, t, -CH,e,). Anal. calcd for 
C27H491N04P.HzO: C, 51.68; H, 8.19; N, 2.23. 
Found: C, 51.92; H, 8.35; N, 2.15. 
Radioiodination by iodine exchange 
Radioiodination of 3 and 5 with iodine-125 was 
accomplished by the same method as for the prep- 
aration of NM-294 reported previously (Counsel1 
et al., 1990). Briefly, the compound (1-2mg) to be 
labeled was treated with Na”‘I (1.3-3 mCi) in pivalic 
acid (15 ~1 L) at 160°C for 45 min. The radioiodinated 
product was purified by silica gel column 
chromatography (1 x 5 cm). A solvent mixture of 
CHCl,: MeOH:H,O (65: 25:4) was used to elute 3, 
whereas CHC& : MeOH (1: 1) was used for elution of 
5. Radiochemical purity of the isolated product was 
established by radio-TLC with unlabeled material 
serving as standard. Radiochemical yields based on 
TLC of exchange reaction mixture was 66 and 72% 
for 3 and 5, respectively. 
Animals 
Female Sprague-Dawley rats, 200-250 g (Charles 
River, Portage, Mich.) were housed in a temperature 
and light-controlled room and had free access to food 
and water. The rats were inoculated with Walker 256 
carcinosarcoma cells (1 .O x 10’ cells) in saline in the 
left and/or right hindlimb. These animals were used 
7-10 days later when the tumor weight averaged 
log. Athymic nude mice, 20-25 g (Charles River, 
Wilmington, Del.) were housed in specific pathogen- 
free rooms and had free access to food and water. 
The mice were inoculated subcutaneously into the 
shoulder region with human carcinoma cells 
(1.0 x lo’cells). These animals were used when the 
tumors were approx. 5 mm in diameter. The time to 
reach this tumor size varied with the different cell 
lines. For example, HTB-63 (human melanoma) and 
NCI-H69 (human small cell carcinoma of the lung) 
cells required 4-6 weeks for tumor growth whereas, 
HTB-77 (human ovarian carcinoma) took 10-14 
days. 
Cell lines and cuIture conditions 
The Walker 256 cell line was provided by Dr James 
Varani of the Department of Pathology, University 
of Michigan. The cells were maintained in RPM1 
1640 medium containing 10% fetal bovine serum 
(FBS), 200 units/ml of penicillin, and 0.2 mg/mL of 
streptomycin. HTB-63 (human melanoma), NCI-H69 
(human small cell carcinoma of the lung) and HTB- 
77 (human ovarian carcinoma) cells were purchased 
from ATCC (American Type Tissue Culture Collec- 
tion). HTB-63 cells were maintained in McCoy’s 5a 
medium plus 10% FBS. NCI-H69 and HTB-77 cells 
were maintained in RPM1 1640 plus 10% FBS. In 
addition, medium for the human cell lines con- 
tained penicillin/streptomycin (final concentration 
of 50 pg penicillin/ml and 50 pg streptomycin/ml) 
and L-glutamine, 200mM (final concentration of 
292pg/mL). All cells were maintained at 37°C in 
a humidified atmosphere of 90% Nz, 5% CO2 and 
5% 01. 
Tissue distribution 
The radiolabeled compounds were dissolved in 
95% EtOH and Tween-20 (0.1 mL/mg of compound) 
was added. The solvent was evaporated with a stream 
of nitrogen. Physiological saline was added, and the 
final traces of solvent were removed by passing 
nitrogen over the solution until it became clear (in 
final solution 2-3% Tween). The solubilized radio- 
labeled compound (15-35 PCi, rats: 0.5-l .O mL, 
mice: 0.1 mL) was administered i.v. via a tail vein to 
tumor-bearing animals. The rats were sacrificed by 
exsanguination and the mice by decapitation while 
under ether anesthesia at the various time points. The 
blood was collected and selected tissues were removed 
and blotted of excess blood. Large organs were 
minced with scissors. Tissue samples were weighed in 
cellulose acetate capsules and counted with a Searle 
1185 well scintillation counter (85% counting 
efficiency). The concentration of radioactivity in each 
tissue was expressed as percentage of administered 
dose per gram of tissue. 
Lipid extraction 
Samples of liver, plasma and tumor were homogen- 
ized in CHCl, : MeOH by the method of Folch et al. 
(1957). Briefly, 0.1 g tissue or 0.1 mL plasma and 
0.4 mL water were homogenized in three washes of 
3 mL each of CHCl,: MeOH (2: 1) and the resulting 
homogenate filtered. The filter paper was air-dried 
and assayed for radioactivity. The filtrate was ad- 
justed to 10 mL with CHC&: MeOH, an additional 
2 mL H,O was added and centrifuged for 10 min at 
800g. The aqueous and organic phases were separ- 
ated. The aqueous phase was adjusted to 5 mL with 
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CHCl,: MeOH: H,O (3:48:47) and a 1 mL aliquot 
was taken for counting. The organic phase was 
evaporated under nitrogen, then redissolved in 1 mL 
of benzene. A 0.1 mL aliquot was taken for counting 
and the remainder was sealed and stored overnight. 
The benzene fraction was dried, then the compound 
resuspended in diethyl ether and spotted on a silica 
gel 60 F-254 thin layer chromatography (TLC) 
plate (Eastman Kodak, Rochester, N.Y. or Merck, 
Darmstadt). After allowing the plates to air dry, 
they were developed in CHCl, : MeOH : HOAc : H,O 
(75 : 25 : 8 : 3) (NM-324) and CHCl, : MeOH (1: 2) 
(NM-326). After removal from the developing tank, 
the plates were allowed to air dry, then scanned using 
a System 200 Imaging Scanner. The radioactivity 
appearing in the lipid extract is expressed as % of 
total radioactivity present on the filter, and both in 
the aqueous and organic phase. 
Gamma-camera imaging of rats and mice 
12-(m-Iodophenyl)dodecylphosphocholine (3, NM- 
324) and hexadecyl-2-[N,N-dimethyl-N-(m-iodo- 
benzyl)ammonium] ethylphosphate (5, NM-326) 
were synthesized as shown in Fig. 3. 12-(m-Iodo- 
phenyl)dodecanol (1) was prepared by the procedure 
reported previously (Meyer et al., 1989). Phosphoryl- 
ation of both 1 and hexadecanol with 2-bromoethyl 
dichlorophosphate gave 12-(m-iodophenyl dodecyl- 
2-bromoethylphosphate (2) and hexadecyl-2-bromo- 
ethylphosphate (4) in 62 and 43% yield, respectively. 
The phosphate (2) was readily converted to the 
choline phosphate (3) in 62% yield by heating with 
trimethylamine in CHCl,: 2-PrOH : DMF (3 : 5 : 5) for 
6 h. Condensation of the phosphate 4 and m-iodo- 
benzylamine was carried out by refluxing in EtOH for 
3 days to give N-iodobenzyl derivative 5 in 29% 
yield. 
Scanning of the animals was done with an Ohio 
Nuclear Mobile Camera with a high sensitivity-low 
energy collimator. Animals were sedated with 
87 mg/kg ketamine and 13 mg/kg xylazine. Images 
were accumulated at various time points follow- 
ing administration of radiolabeled compound 
(35-75 PCi). 
To evaluate the potential of NM-324 and NM-326 
as tumor localizing agents, scintigraphic images were 
obtained at various time points following injection as 
shown in Fig. 4. Administration of NM-324 to a rat 
bearing a Walker carcinosarcoma in the hind limbs 
produced excellent images of the tumors. A high 
background activity was seen in the abdominal area 
at the early time points with subsequent clearing. 
Results and Discussion 
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Fig. 3. Synthesis of radioiodinated analogs of alkylphosphocholine, NM-324 and NM-326. 
1 1 
24h 32h 
Acquisition time 4.1 min Acqulsltlon time 6.2 min 
120h 120 h 
Acqulsltron time 59min Acquisition time 120 min 
Fig. 4. Gamma-camera scintigraphy at various time periods following administration of NM-324 and 
NM-326 of rats bearing Walker 256 tumors implanted in the thighs. The dose administered and the time 
to accumulate 100,000 counts are shown. 
NM -324 NM -326 
769 
NM-324 in athymic mice bearing human tumors 
Ovarion carcinoma 
Small cell carcinoma 
Melanoma 
Day 5 Day 0 Day 12 
Fig. 7. Gamma-camera scintigraphy of athymic mice bearing human tumors at 5, 8 and 12 days following 
administration of NM-324. The dose administered was 30 HCi. 
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Adrenal Blood Duodenum Kidney Liver Lung Tumor 
Fig. 5. Distribution of radioactivity following i.v. administration of radioiodinated analogs in tumor- 
bearing rats at 24 h. The dose administered was 15 PCi. 
NM-326 also produced good images of the tumors, 
but had even higher background activity. In addition, 
a comparison of the image acquisition time for the 
two compounds showed that NM-326, at a dose of 
85 PCi, took longer to acquire 100,000 counts than 
NM-324 at a smaller dose of 58 PCi (Fig. 4). This 
suggested that the NM-326 was being rapidly cleared 
from the animal while NM-324 was being retained by 
the tumor. 
Tissue distribution studies with NM-324 in the rat 
bearing the Walker tumor at 24 h post-injection 
demonstrated the tumor to accumulate 10.5% of the 
dose. On the other hand, only 2% of the dose of 
NM-326 was taken up by the tumor at 24 h (Fig. 5). 
In addition, NM-326 showed minimal uptake of 
radioactivity in all tissues. Earlier time points (data 
not shown) for NM-326 showed high levels of radio- 
activity in liver, duodenum and kidneys with sub- 
sequent clearing by 24 h. Most of the radioactivity 
appeared to be eliminated shortly after injection. 
NM-324 also showed (Fig. 6) high levels of radio- 
activity in the duodenum, kidneys and liver which 
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Fig. 6. Distribution of radioactivity of NM-324 in the tumor-bearing rat at various time periods following 
administration. 
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Table I. Lipid soluble radioactivity extracted 
from rat liver, plasma and tumor following i.v. 
administration of NM-324 and NM-326* 
declined with time. Clearance of radioactivity from 















73.w 80.5 + I.4 
69.2 49.4 f 7. I 
77.4 72.9 + I .8 
6h 
69.9t 77.1 + 3.6 
61.8 50.1 * 9.1 
75.4 72.5 f 1.9 
24h 
74.4 f 3.7 76.9 f 2.8 
66.7 f 13.8 66.4 + I I .4 
64.0 f 9. I 76.9 f 2.8 
48h 
Liver 84.4 + 5.9 
Plasma 77. I f 3.5 - 
Tumor 78.0 + 2.1 
5 days 
Liver 76.7 k 12.1 
Plasma 67.8 + 2.9 
Tumor 13.1 + 4.7 
*Percent + SEM; N = 3-4; tumored animals 
had Walker 256 carcinosarcoma implanted 
in thigh. 
tN=l. 
radioactivity peaking at 48 h. 
These encouraging results with NM-324 prompted 
further evaluation in athymic mice bearing sub- 
cutaneous human tumors such as the HTB-63 
(melanoma), NCI-H69 (small cell carcinoma of the 
lung) and HTB-77 (ovarian carcinoma). Gamma- 
camera scintigraphy at 5 days post-injection showed 
tumor localization with a high backgound activity. 
By 8 and 12 days the background activity had cleared 
from the liver and GI tract leaving clear images of the 
tumors (Fig. 7). Tissue distribution data obtained on 
these mice following the last day of scanning showed 
tissue/blood levels > 25/l in all three models (data 
not shown). 
Lipid extraction of the liver from tumored rats at 
3,6,24,48 h and 5 days (NM-324) and 3,6 and 24 h 
(NM-326) demonstrated that most of the radioac- 
tivity present was lipid extractable (Table 1). Thin 
layer chromatography of the organic phases at 24 and 
120 h showed that most of the radioactivity remained 
associated with the parent compound for NM-324 in 
the liver and tumor (Fig. 8). There was a much lower 
level of lipid extractable radioactivity from the 





Fig. 8. Thin layer chromatography of parent compound and lipid extracts of liver and tumor from rats 
bearing a Walker 256 tumor at 24 and 120 h following administration of NM-324. The solvent system 
used was CHCl,:MeOH:HOAc:H,O (75:25:8:3). The origin was at 4.Ocm and the solvent front at 
17em. Pure radiolabeled compound used for administration was employed as the reference standard. 
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plasma suggesting clearance of the radioactivity over 
time. 
With NM-326 the percent of radioactivity associ- 
ated with the parent compound remained stable over 
time in the liver and tumor tissue. This coupled with 
the fact that nondetectable levels were seen in the 
plasma suggested that the parent compound was 
cleared from the animal fairly rapidly. 
Based on these studies with two structural analogs 
of APC, it is clear that certain structural features are 
required for optimal retention of these molecules in 
tumors. In contrast to NM-324, NM-326 showed 
poor accumulation in the Walker 256 carcinosarcoma 
tumor. Basically these compounds differ only by the 
placement of the iodophenyl marker moiety. Place- 
ment of this group on the choline portion of the 
molecule markedly altered the ability to localize in 
the tumor. Other investigators have shown that alter- 
ation of this portion of the molecule either by replac- 
ing with a phosphoinositol group (Noseda et al., 
1987) or by lengthening the carbon chain (Schick 
et al., 1987) causes a decrease in tumor cytotoxicity. 
In summary, radioiodinated analogs of APC rep- 
resent a new class of agents whose excellent tumor 
uptake suggests that they may have potential clinical 
use not only as noninvasive tumor imaging agents but 
also as candidates for tumor therapy. 
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